CA3247602A1 - Treatment of a non-alcoholic fatty liver disease - Google Patents
Treatment of a non-alcoholic fatty liver diseaseInfo
- Publication number
- CA3247602A1 CA3247602A1 CA3247602A CA3247602A CA3247602A1 CA 3247602 A1 CA3247602 A1 CA 3247602A1 CA 3247602 A CA3247602 A CA 3247602A CA 3247602 A CA3247602 A CA 3247602A CA 3247602 A1 CA3247602 A1 CA 3247602A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- human subject
- dose
- methyl
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263329081P | 2022-04-08 | 2022-04-08 | |
| US63/329,081 | 2022-04-08 | ||
| US202263401858P | 2022-08-29 | 2022-08-29 | |
| US63/401,858 | 2022-08-29 | ||
| PCT/US2023/065487 WO2023196941A1 (en) | 2022-04-08 | 2023-04-07 | Treatment of a non-alcoholic fatty liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3247602A1 true CA3247602A1 (en) | 2023-10-12 |
Family
ID=86286479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3247602A Pending CA3247602A1 (en) | 2022-04-08 | 2023-04-07 | Treatment of a non-alcoholic fatty liver disease |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250283089A1 (https=) |
| EP (1) | EP4504337A1 (https=) |
| JP (1) | JP2025511854A (https=) |
| CN (1) | CN119789859A (https=) |
| CA (1) | CA3247602A1 (https=) |
| WO (1) | WO2023196941A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025074157A1 (en) * | 2023-10-06 | 2025-04-10 | Glaxosmithkline Intellectual Property (No.3) Limited | Treatment of a non-alcoholic fatty liver disease |
| WO2025162271A1 (zh) * | 2024-02-03 | 2025-08-07 | 北京福元医药股份有限公司 | 用于抑制HSD17B13表达的siRNA、其缀合物和药物组合物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102515329B1 (ko) | 2016-03-07 | 2023-03-29 | 애로우헤드 파마슈티컬스 인코포레이티드 | 치료용 화합물을 위한 표적화 리간드 |
| MX2018009853A (es) | 2016-09-02 | 2018-11-09 | Arrowhead Pharmaceuticals Inc | Ligandos de direccion. |
| MX2020001912A (es) * | 2017-09-14 | 2020-03-24 | Arrowhead Pharmaceuticals Inc | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso. |
| MX2021003077A (es) | 2018-09-19 | 2021-05-27 | Arrowhead Pharmaceuticals Inc | Agentes de arni para inhibir la expresion de 17beta-hsd tipo 13 (hsd17b13), composiciones de dichos agentes, y metodos de uso. |
| TW202202153A (zh) * | 2020-03-26 | 2022-01-16 | 美商艾羅海德製藥公司 | 用於抑制ＰＮＰＬＡ３表現之ＲＮＡｉ劑、其醫藥組成物及使用方法 |
-
2023
- 2023-04-07 CN CN202380045597.9A patent/CN119789859A/zh active Pending
- 2023-04-07 JP JP2024559398A patent/JP2025511854A/ja active Pending
- 2023-04-07 CA CA3247602A patent/CA3247602A1/en active Pending
- 2023-04-07 EP EP23721243.6A patent/EP4504337A1/en active Pending
- 2023-04-07 WO PCT/US2023/065487 patent/WO2023196941A1/en not_active Ceased
- 2023-04-07 US US18/854,700 patent/US20250283089A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250283089A1 (en) | 2025-09-11 |
| EP4504337A1 (en) | 2025-02-12 |
| JP2025511854A (ja) | 2025-04-16 |
| WO2023196941A1 (en) | 2023-10-12 |
| CN119789859A (zh) | 2025-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI870358B (zh) | 用於抑制17β-HSD第13型(HSD17B13)表現之RNAi藥劑、其組合物及使用方法 | |
| TWI784934B (zh) | 抑制lpa之基因表現之組合物及方法 | |
| TW202307207A (zh) | 用於抑制黃嘌呤脫氫酶(XDH)之表現之RNAi藥劑、其醫藥組合物及使用方法 | |
| JP7830340B2 (ja) | ＰＮＰＬＡ３の発現を阻害するためのＲＮＡｉ薬、その医薬組成物、及び使用方法 | |
| US12582668B2 (en) | Methods for the treatment of alpha-1 antitrypsin deficiency (AATD) | |
| JP2021522804A (ja) | Ｆｘｉの発現を低下させるための化合物及び方法 | |
| JP7829478B2 (ja) | Ａｐｏｃ３関連疾患および障害の処置のための方法 | |
| US20250283089A1 (en) | Treatment of a non-alcoholic fatty liver disease | |
| JP2020537653A (ja) | アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物 | |
| CN120112639A (zh) | Angptl3相关疾病和病症的治疗方法 | |
| US20230348905A1 (en) | Methods for the reduction of z-aat protein levels | |
| JP2025032231A (ja) | Ｓｅｒｐｉｎｃ１ ｉＲＮＡ組成物およびその使用方法 | |
| CN116670278A (zh) | 用于降低z-aat蛋白水平的方法 | |
| WO2025074157A1 (en) | Treatment of a non-alcoholic fatty liver disease | |
| AU2020324974B2 (en) | Methods for the treatment of APOC3-related diseases and disorders | |
| TW202430635A (zh) | 用於抑制補體成分C3(C3)表現之RNAi藥劑、其醫藥組合物及使用方法 | |
| CN121969377A (zh) | 非酒精性脂肪性肝病的治疗 | |
| CN121127587A (zh) | 用于抑制LPA表达的RNAi剂及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241004 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241023 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241023 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241023 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241119 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250320 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250808 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260319 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260319 |